Second Regular Session | 74th General Assembly
Colorado General AssemblyThe Interim Committee on Opiod and other Substance Use Disorders was created pursuant to Section 10-22.3-101.
During the 2017 legislative session, the General Assembly considered several measures related to Medicaid, insurance carriers, and substance use disorder in Colorado. The General Assembly also considered measures related to background checks for some types of providers and made changes to the...
Final Report to the Colorado General Assembly by the Opioid and Other Substance Use Disorders Interim Study Committee.
During the 2017 legislative session, the General Assembly considered measures related to Colorado’s behavioral health crisis system and the use and misuse of opioids. Other issues considered include child care regulations, child welfare, and a job program for individuals receiving cash...
Presented to the TLRC at its November 2, 2017 meeting.
This memorandum addresses patient access to experimental treatments, including access to clinical trials, participation in the U.S. Food and Drug Administration’s Expanded Access (Compassionate Use) Program, and access to treatments under Colorado’s Right to Try Act. Additionally, this...
This issue brief explains Colorado’s Temporary Assistance for Needy Families (TANF) program, known as Colorado Works, which provides financial and other assistance. The federally funded program is overseen at the state level by the Department of Human Services and is administered at the county...
This issue brief addresses the state’s emergency mental health hold procedure, which allows for a person to be involuntarily held for a 72-hour period of treatment and evaluation if he or she appears to have a mental illness and, due to the mental illness, appears to be an imminent danger to...
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorders Interim Study Committee at its September 2017 meeting.
Presented to the Opioid and Other Substance Use Disorder Interim Study Committee at its September 2017 meeting.